ArticleOncotarget2016
Prognostic and predictive value of Ki-67 in triple-negative breast cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- The role of AI-driven decision support in immunotherapy for predicting pathological complete response in triple-negative breast cancer.Frontiers in oncology · 2026Article
- ALKBH7 and NLRP3 Co-Expression: A Potential Prognostic and Immunometabolic Marker Set in Breast Cancer Subtypes.International journal of molecular sciences · 2025Article
- Microbial community profiles in breast cancer and normal adjacent tissues: associations with clinicopathological characteristics.Translational cancer research · 2025Article
- Predictive value of serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, KI-67 in breast cancer: A systematic review and meta-analysis.Journal of medical biochemistry · 2025Article
- Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer.BJC reports · 2024Article
- Deciphering the Role of BRAFV600E Immunohistochemistry in Breast Lesions: A Comprehensive Review.Cureus · 2024Review
- Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients.Life (Basel, Switzerland) · 2024Article
- Axillary lymph node metastasis in pure mucinous carcinoma of breast: clinicopathologic and ultrasonographic features.BMC medical imaging · 2024Article
- Prognostic predictive value of Ki-67 in stage I-II triple-negative breast cancer.Future science OA · 2024Article
- Does a 40% Cut-off Point for Ki-67 Expression Have a Role in Identifying the Development of Distant Metastasis Within 2 Years in Locally Advanced Triple Negative Breast Cancer Patients?European journal of breast health · 2023Article
- Article
- Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.Frontiers in oncology · 2023Article
- The expression of androgen receptor in triple-negative breast cancer and the effect of a traditional Chinese medicine formula on disease-free survival.Gland surgery · 2022Article
- Fatty acid synthetase expression in triple-negative breast cancer.Journal of pathology and translational medicine · 2022Article
- Ki-67 proliferation index to further stratify invasive breast cancer molecular subtypes: Northern African comparative cohort-study with external TCGA-BRCA and METABRIC validation.The Pan African medical journal · 2022Article
- [Application Test of the AI-Automatic Diagnostic System for Ki-67 in Breast Cancer].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021Article
- Article
- KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance.Breast cancer : basic and clinical research · 2021Article
- Prevalence and Spectrum ofGenes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was to investigate the prognostic role of Ki-67 in further classification of triple negative breast cancer (TNBC), and to test whether high expression level of Ki67 can predict benefit from carboplatin. From January 2004 to December 2012, 363 patients operated for TNBC were identified through the institutional clinical database. After a median follow-up time of 34 months (5.2-120.0 months), 62 patients (17.1%) had relapses and 33 patients (9.1%) died of breast cancer. In univariate analysis, high Ki-67 index as well as larger tumor size and lymph node involvement was associated with shorter disease-free survival (DFS) and overall survival (OS). In multivariate analysis, high Ki-67 is an independent risk factor for DFS (Risk Ratio, RR: 2.835, 95% confidence interval, 95% CI: 1.586-5.068, P < 0.001) and OS (RR: 3.180, 95% CI: 1.488-6.793, P = 0.003). When analyzing the 3-year DFS by Ki-67 distribution, Subpopulation Treatment Effect Pattern Plot analysis showed a beneficial effect of carboplatin in patients with high Ki-67 index. In conclusion, TNBC is probably a heterogeneous disease with different characteristics and prognosis, and may be further subdivided according to the Ki-67 expression levels. Patients in the high Ki- 67 group seem to benefit more from treatment with carboplatin, but this needs to be further verified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.